CLINICAL TRIALS PROFILE FOR DEPO-MEDROL

All Clinical Trials for Depo-medrol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002831 ↗	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	1995-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002831 ↗	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia	Completed	M.D. Anderson Cancer Center	Phase 1/Phase 2	1995-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002833 ↗	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002833 ↗	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	M.D. Anderson Cancer Center	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002835 ↗	Combination Chemotherapy in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	1995-10-30	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.

Clinical Trial Conditions for Depo-medrol

Condition Name

Condition Name for Depo-medrol
Intervention	Trials
Leukemia	15
Osteoarthrosis	6
Acute Lymphoblastic Leukemia	6
Graft Versus Host Disease	6

Condition MeSH

Condition MeSH for Depo-medrol
Intervention	Trials
Leukemia	22
Leukemia, Lymphoid	16
Precursor Cell Lymphoblastic Leukemia-Lymphoma	15
Syndrome	13

Clinical Trial Locations for Depo-medrol

Trials by Country

Trials by Country for Depo-medrol
Location	Trials
United States	420
Canada	42
China	16
Denmark	14
Australia	12

Trials by US State

Trials by US State for Depo-medrol
Location	Trials
Texas	30
California	21
Ohio	17
New York	16
Indiana	15

Clinical Trial Progress for Depo-medrol

Clinical Trial Phase

Clinical Trial Phase for Depo-medrol
Clinical Trial Phase	Trials
Phase 4	18
Phase 3	20
Phase 2/Phase 3	6

Clinical Trial Status

Clinical Trial Status for Depo-medrol
Clinical Trial Phase	Trials
Completed	57
Recruiting	18
Active, not recruiting	12

Clinical Trial Sponsors for Depo-medrol

Sponsor Name

Sponsor Name for Depo-medrol
Sponsor	Trials
National Cancer Institute (NCI)	20
M.D. Anderson Cancer Center	16
Bispebjerg Hospital	7

Sponsor Type

Sponsor Type for Depo-medrol
Sponsor	Trials
Other	130
Industry	39
NIH	32

DEPO-MEDROL (Methylprednisolone): Clinical Trials, Market Analysis, and Projections

Introduction

DEPO-MEDROL, a formulation of methylprednisolone acetate, is a widely used corticosteroid with broad applications in various medical conditions. This article will delve into recent clinical trials, market analysis, and future projections for this drug.

Clinical Trials Update

Methylprednisolone in Acute Ischemic Stroke

A significant recent clinical trial is the MARVEL (Methylprednisolone as Adjunctive to Endovascular Treatment for Acute Large Vessel Occlusion) trial. This investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial was conducted at 82 comprehensive stroke centers in China. The trial involved 1680 patients with acute ischemic stroke who were randomly assigned to receive either intravenous methylprednisolone at 2 mg/kg/day or a placebo for three days, in addition to endovascular thrombectomy.

The results showed that the addition of methylprednisolone did not significantly improve the overall disability outcomes as measured by the modified Rankin Scale (mRS) at 90 days. However, there was a lower mortality rate (23.2% vs 28.5%) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%) in the methylprednisolone group compared to the placebo group[1].

Indications and Usage

DEPO-MEDROL is indicated for a wide range of conditions, including:

• Allergic States: Control of severe or incapacitating allergic conditions such as asthma, atopic dermatitis, and drug hypersensitivity reactions.
• Dermatologic Diseases: Treatment of conditions like bullous dermatitis herpetiformis, exfoliative erythroderma, and severe erythema multiforme.
• Rheumatic Disorders: Adjunctive therapy for acute gouty arthritis, rheumatoid arthritis, and psoriatic arthritis.
• Other Conditions: Use in acute nonspecific tenosynovitis, epicondylitis, and systemic lupus erythematosus[3][4].

Market Analysis

Market Size and Growth

The global methylprednisolone market is projected to grow significantly over the coming years. By 2027, the market size is estimated to reach $917.4 million, growing at a Compound Annual Growth Rate (CAGR) of 3.4% from 2022 to 2027. This growth is driven by the increasing prevalence of autoimmune disorders and other inflammatory diseases[5].

Market Segmentation

The methylprednisolone market can be segmented by product type, application, and geography.

• Product Type: The market is primarily split into infusion type and oral type. The infusion type is further segmented into sublingual films and fully dissolving dental/buccal films[5].
• Application: The drug is used in various medical conditions, with rheumatic disorders being the fastest-growing segment due to rising risk factors such as old age, smoking, and obesity[5].
• Geography: North America holds a dominant market share, but the Asia-Pacific region is expected to offer lucrative growth opportunities due to increasing healthcare expenditure and awareness about better medical conditions[5].

Distribution Channels

The market is segmented into offline and online retail channels, with offline retail holding a dominant share due to the urgent nature of allergic conditions that often require immediate treatment in hospital settings[5].

Market Drivers

Growing Prevalence of Autoimmune Disorders

The increasing prevalence of autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis is a significant driver for the methylprednisolone market. These conditions require long-term management, which includes the use of corticosteroids like methylprednisolone[5].

Rising Healthcare Expenditure

Increased healthcare expenditure, particularly in regions like Asia-Pacific, is driving the demand for better medical treatments, including the use of methylprednisolone. For instance, India's healthcare expenditure rose by up to 137% in 2021, indicating a growing market[5].

Market Challenges

Side Effects and Contraindications

Methylprednisolone, like other corticosteroids, has several side effects and contraindications. It is contraindicated in patients with known hypersensitivity to the product, idiopathic thrombocytopenic purpura, and systemic fungal infections. These limitations can affect its market growth[3][4].

Regulatory Scrutiny

Clinical trials and regulatory approvals are crucial for the market success of any drug. The MARVEL trial's findings, for example, may influence future regulatory decisions and clinical guidelines for the use of methylprednisolone in acute ischemic stroke[1].

Future Projections

Market Growth Opportunities

The Asia-Pacific region is expected to offer significant growth opportunities due to increasing awareness and healthcare expenditure. The growing geriatric population and rising obesity rates are also expected to drive the demand for methylprednisolone in managing related health conditions[5].

Competitive Landscape

The global methylprednisolone market is competitive, with key players such as ENDO, Pharmacia, TEVA, SANDOZ, Pfizer, and JUBILANT CADISTA. These companies are expected to continue innovating and expanding their product lines to capture a larger market share[2].

Key Takeaways

• Clinical Trials: Recent trials like the MARVEL trial have shown mixed results, highlighting the need for further research on the efficacy of methylprednisolone in specific conditions.
• Market Growth: The global methylprednisolone market is projected to grow at a CAGR of 3.4% from 2022 to 2027, driven by increasing prevalence of autoimmune disorders and rising healthcare expenditure.
• Market Segmentation: The market is segmented by product type, application, and geography, with North America currently holding a dominant share but Asia-Pacific offering future growth opportunities.
• Challenges: Side effects, contraindications, and regulatory scrutiny are key challenges that need to be addressed.

FAQs

What are the primary indications for DEPO-MEDROL?

DEPO-MEDROL is indicated for allergic states, dermatologic diseases, rheumatic disorders, and other inflammatory conditions.

What were the findings of the MARVEL trial?

The MARVEL trial found that adjunctive methylprednisolone therapy did not significantly improve overall disability outcomes in patients with acute ischemic stroke but did reduce mortality and symptomatic intracranial hemorrhage rates.

What is the projected market size of methylprednisolone by 2027?

The global methylprednisolone market is estimated to reach $917.4 million by 2027.

Which region is expected to offer the most growth opportunities for methylprednisolone?

The Asia-Pacific region is expected to offer significant growth opportunities due to increasing healthcare expenditure and awareness.

What are the main side effects and contraindications of methylprednisolone?

Methylprednisolone has several side effects and is contraindicated in patients with known hypersensitivity, idiopathic thrombocytopenic purpura, and systemic fungal infections.

Sources

1. JAMA Network: Methylprednisolone as Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke.
2. PharmiWeb: Global Methylprednisolone Market 2020 – Industry Dynamics, Segmentation and Competition Analysis 2025.
3. Pfizer: DEPO-MEDROL (methylprednisolone acetate injectable suspension) Label.
4. FDA: DEPO-MEDROL (methylprednisolone acetate injectable suspension) Label.
5. IndustryARC: Methylprednisolone Market - Forecast(2024 - 2030).

Last updated: 2025-01-04